Ocular Therapeutix (OCUL) Price Target Raised to $50 at RBC
RBC Capital maintained an Outperform rating on Ocular Therapeutix (NASDAQ: OCUL) and raised its price target to $50.00 (from $35.00).
Analyst Adnan Butt said, "OCUL’s platform technology is already paying off with: (1) One positive Phase III reading out, (2) 5 clinical programs (2 Phase IIIs and 2 Phase IIs), (3) Pipeline surprises (upside optionality), (4) Blockbuster potential indications (at least 2–3), (5) Likelihood of partnerships or take outs, and (6) Continuous news flow. We are raising our price target, especially to reflect the anti-VEGF program potential."
For an analyst ratings summary and ratings history on Ocular Therapeutix click here. For more ratings news on Ocular Therapeutix click here.
Shares of Ocular Therapeutix closed at $40.25 yesterday.